Aquestive Therapeutics, Inc.

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
3.22 ^USD	+0.62%		+4.38%	+59.41%

May. 10	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	MT
May. 08	Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Aquestive Therapeutics, Inc. Announces Resignation of John Maxwell as Senior Vice President

December 16, 2020 at 08:00 am EST

Aquestive Therapeutics, Inc. announced that John Maxwell, Senior Vice President of the Company has provided his intent to resign his position with the company to pursue other interests.

Latest news about Aquestive Therapeutics, Inc.

Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	May. 10	MT
Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q1 Revenue $12.1M, vs. Street Est of $12.3M	May. 07	MT
Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	May. 07	CI
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children	Apr. 29	MT
Transcript : Aquestive Therapeutics, Inc. - Special Call	Apr. 29
Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film	Apr. 29	CI
Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	Apr. 12	CI
Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	Apr. 11	MT
Aquestive Therapeutics Files $250 Million Mixed Shelf	Apr. 03	MT
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024	Apr. 01	CI
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	Mar. 28	MT
Top Midday Decliners	Mar. 20	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	Mar. 20	MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20	MT
Top Premarket Decliners	Mar. 20	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket	Mar. 20	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering	Mar. 20	MT
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop	Mar. 19	MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	Mar. 18	MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	Mar. 15	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 15	MT
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial	Mar. 14	MT
Aquestive Therapeutics, Inc. Releases Positive Topline Clinical Data from Its Phase 3 Pivotal Pharmacokinetic (PK) Clinical Study of Anaphylm (Epinephrine) Sublingual Film and Findings from the FDA Type C meeting	Mar. 14	CI

Chart Aquestive Therapeutics, Inc.

Duration

Period

More charts

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Companyâs Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Sector

Pharmaceuticals

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Aquestive Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.22 USD

Average target price

8.611 USD

Spread / Average Target

+167.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AQUESTIVE THERAPEUTICS, INC.	+59.41%	293M
NOVO NORDISK A/S	+31.37%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	211B
ROCHE HOLDING AG	-6.95%	203B
AMGEN INC.	+10.77%	171B
PFIZER, INC.	+0.10%	163B

Other Pharmaceuticals